Ulcerative Colitis (UC) Market in China 2021
The ulcerative colitis (UC) market in China in terms of revenue is set to grow by US$ 1 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 16.5% during the forecast period, according to data and analytics company StrategyHelix.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for ulcerative colitis (UC). The China ulcerative colitis (UC) market is segmented on the basis of type, product. By type, it is categorized into mild ulcerative colitis, and moderate to severe ulcerative colitis. By product, the ulcerative colitis (UC) market is divided into infliximab, mesalazine, sulfasalazine (SSZ), and others.
The report has profiled some of the key players of the market such as Losan Pharma GmbH, Ferring Holding SA, Guangdong Qiangji Pharmaceutical Co. Ltd., Janssen Pharmaceuticals Inc., Shanghai Sine Tianping Pharmaceutical Co. Ltd..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the ulcerative colitis (UC) market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Type: mild ulcerative colitis, and moderate to severe ulcerative colitis
Product: infliximab, mesalazine, sulfasalazine (SSZ), and others
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China ulcerative colitis (UC) market
Pinpoint growth sectors and trends for investment
Understand what the future of the ulcerative colitis (UC) market in China looks like
Identify the competitive landscape and window of opportunity
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for ulcerative colitis (UC). The China ulcerative colitis (UC) market is segmented on the basis of type, product. By type, it is categorized into mild ulcerative colitis, and moderate to severe ulcerative colitis. By product, the ulcerative colitis (UC) market is divided into infliximab, mesalazine, sulfasalazine (SSZ), and others.
The report has profiled some of the key players of the market such as Losan Pharma GmbH, Ferring Holding SA, Guangdong Qiangji Pharmaceutical Co. Ltd., Janssen Pharmaceuticals Inc., Shanghai Sine Tianping Pharmaceutical Co. Ltd..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the ulcerative colitis (UC) market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Type: mild ulcerative colitis, and moderate to severe ulcerative colitis
Product: infliximab, mesalazine, sulfasalazine (SSZ), and others
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China ulcerative colitis (UC) market
Pinpoint growth sectors and trends for investment
Understand what the future of the ulcerative colitis (UC) market in China looks like
Identify the competitive landscape and window of opportunity
1. MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. ULCERATIVE COLITIS (UC) MARKET BY TYPE
4.1 Mild Ulcerative Colitis
4.2 Moderate To Severe Ulcerative Colitis
5. ULCERATIVE COLITIS (UC) MARKET BY PRODUCT
5.1 Infliximab
5.2 Mesalazine
5.3 Sulfasalazine (Ssz)
5.4 Others
6. COMPANY PROFILES
6.1 Losan Pharma GmbH
6.2 Ferring Holding SA
6.3 Guangdong Qiangji Pharmaceutical Co., Ltd.
6.4 Janssen Pharmaceuticals, Inc.
6.5 Shanghai Sine Tianping Pharmaceutical Co., Ltd.
7. APPENDIX
7.1 About StrategyHelix
7.2 Disclaimer
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. ULCERATIVE COLITIS (UC) MARKET BY TYPE
4.1 Mild Ulcerative Colitis
4.2 Moderate To Severe Ulcerative Colitis
5. ULCERATIVE COLITIS (UC) MARKET BY PRODUCT
5.1 Infliximab
5.2 Mesalazine
5.3 Sulfasalazine (Ssz)
5.4 Others
6. COMPANY PROFILES
6.1 Losan Pharma GmbH
6.2 Ferring Holding SA
6.3 Guangdong Qiangji Pharmaceutical Co., Ltd.
6.4 Janssen Pharmaceuticals, Inc.
6.5 Shanghai Sine Tianping Pharmaceutical Co., Ltd.
7. APPENDIX
7.1 About StrategyHelix
7.2 Disclaimer
